Peanut (Ara h 15) IgE Test · Blood

Peanut allergy is one of the most common causes of severe, sometimes life-threatening food reactions, and the underlying biology comes down to a single class of antibodies: immunoglobulin E (IgE) directed at peanut proteins. Different peanut proteins carry different levels of risk, and modern testing now breaks the response apart into individual components rather than treating peanut as one big target.

Ara h 15 IgE (immunoglobulin E specific to peanut allergen number 15) is one such component-level measurement. It is a newer, research-focused marker without standardized clinical cutpoints, so a single number cannot diagnose or rule out peanut allergy on its own. Reading it alongside established markers and your own history is what gives it value.

What This Test Actually Measures

The blood test measures IgE antibodies in your blood that specifically bind to the Ara h 15 peanut protein. IgE is the antibody class your body produces during an allergic immune response. When you encounter peanut and have these antibodies, they can attach to immune cells called mast cells and basophils, triggering the chemical release that causes symptoms like hives, swelling, breathing trouble, or anaphylaxis (a severe whole-body allergic reaction).

A key point of clarity: the bulk of peanut allergy research focuses on other peanut components, especially Ara h 2, along with Ara h 1, 3, 6, 8, and 9. Published studies on peanut diagnosis, severity prediction, and treatment outcomes have not specifically measured Ara h 15 IgE. So while the underlying biology of IgE-mediated peanut allergy is well established, the specific clinical meaning of an Ara h 15 IgE result is still being worked out.

Why Peanut Component Testing Matters at All

Traditional peanut allergy testing uses a skin prick test or a blood IgE test against whole peanut extract. Both are sensitive but not very specific, which means many people who test positive can actually eat peanut without reacting. In one population-based assessment of children, only a minority of those who tested sensitized to peanut were truly allergic when confirmed by challenge.

Component testing separates the immune response to individual peanut proteins. Among well-studied components, Ara h 2 has the highest diagnostic accuracy. In a study of high-risk infants tested before peanut introduction, Ara h 2 IgE achieved high sensitivity and specificity for true peanut allergy, outperforming whole peanut extract IgE and skin prick testing. A meta-analysis covering component-resolved peanut diagnostics confirmed Ara h 2 as the most specific blood marker for clinical peanut allergy.

Ara h 15 sits within this same family of testing logic. The hope of component-level markers is to identify finer patterns of sensitization than whole-peanut testing can show. Whether Ara h 15 specifically adds independent information beyond Ara h 2 has not been established in published research.

What a Result Can and Cannot Tell You

Because Ara h 15 has not been directly studied for diagnostic thresholds or outcome prediction, no validated cutpoint exists for what counts as elevated, borderline, or protective. Any positive result reflects the presence of IgE binding to this specific peanut protein, which indicates sensitization (your immune system has reacted to it) but does not by itself confirm clinical allergy.

What is known from research on related peanut components applies as broader context, not as direct interpretation of this marker:

• Sensitization is not allergy: many people with detectable peanut-specific IgE can still eat peanut without reacting, particularly when the IgE targets cross-reactive minor components rather than the major storage proteins.
• Higher peanut and Ara h 2 IgE generally track with greater reaction risk during oral food challenges, but with substantial individual overlap. The same logic likely applies in spirit to other components but has not been quantified for Ara h 15.
• A single component IgE measurement does not reliably predict severity of any future reaction. Even the best-studied marker, Ara h 2, cannot replace an oral food challenge for confirming or ruling out true allergy.

How This Fits With Standard Peanut Testing

If you have already had whole-peanut IgE testing or skin prick testing, an Ara h 15 IgE result is most useful as one more piece of a layered picture, not as a verdict. Across multiple studies, the best-supported clinical sequence for adults and children with suspected peanut allergy uses whole peanut IgE or skin prick testing first, then Ara h 2 (and sometimes Ara h 6) IgE to refine diagnosis, and an oral food challenge when results are still unclear.

Adding Ara h 15 to this picture is exploratory. It may eventually help characterize unusual or partial sensitization patterns, but current published evidence does not show that it changes management decisions on its own.

Severity and Threshold of Reaction

For peanut as a whole, higher specific IgE to peanut and to Ara h 2 has been linked to a greater chance of having a positive reaction during a supervised oral food challenge and to reactions at lower doses of peanut. In a large meta-analysis of food allergy risk factors, IgE sensitization was identified as a poor standalone predictor of severe reactions, meaning a high IgE number does not automatically equal a worse reaction, and a low number does not guarantee mildness.

Functional cellular tests such as the basophil activation test (a lab test that measures how strongly your blood cells respond when exposed to peanut) outperform IgE quantity alone for identifying people at high risk of severe reactions. These are typically available only in specialized allergy centers.

Natural History and Resolution

Some children outgrow peanut allergy. In a longitudinal study following children with infant peanut allergy, roughly one third had resolved by age 10. Falling Ara h 2 IgE and rising peanut-specific IgG4 (a related antibody class that appears to be protective) tracked with this resolution. Whether Ara h 15 IgE moves in the same direction during natural tolerance development has not been measured.

Tracking Your Trend

Because no standardized clinical cutpoint exists for Ara h 15 IgE, a single reading carries even less standalone meaning than for an established marker. Tracking the trajectory matters more than any one number. Repeated measurements let you see whether your immune response to this specific peanut protein is rising, falling, or stable, and they give you your own baseline to compare against as the science matures.

A reasonable approach: get a baseline result, then retest after about 6 to 12 months, especially if your peanut-related history changes (such as a reaction, a deliberate avoidance period, or starting any allergy-directed therapy under medical supervision). For children where peanut allergy is being actively managed, annual or more frequent testing in coordination with an allergist is typical for the established components.

When Results Can Be Misleading

Several factors can distort a single component IgE reading. Knowing about them up front protects you from acting on a misleading number.

• Cross-reactivity with other allergens: IgE that detects peanut components can sometimes reflect prior exposure to related plant proteins (such as pollen or tree nuts) rather than a true peanut-specific reaction. This is particularly recognized for Ara h 8 and Ara h 9, and could in principle apply to other components.
• Sensitization without symptoms: a positive IgE result does not require any history of a peanut reaction. People who tolerate peanut can still show detectable peanut-specific IgE.
• Total IgE context: very high total IgE (driven by eczema, parasitic infection, or other allergies) can shift the interpretation of any single allergen-specific IgE. Component testing helps but does not eliminate this effect.
• Laboratory variation: different testing platforms can give different numbers for the same blood sample. If you compare results over time, try to use the same lab and the same assay.

What to Do With an Out-of-Pattern Result

If your Ara h 15 IgE comes back detectable and you have no history of peanut symptoms, do not change your diet based on this single number. The most useful next steps are: order or review companion tests (whole peanut IgE plus Ara h 2 and Ara h 6 IgE) to put the result in context, see an allergist if you have any history of suspected reactions, and never attempt a home peanut challenge if any concern exists. Allergists can offer supervised oral food challenges, which remain the most accurate way to confirm or rule out true clinical peanut allergy.

If you already have known peanut allergy and are tracking your immune response over time, an isolated change in Ara h 15 IgE is not yet a basis for changing avoidance, dosing of any immunotherapy, or carrying of emergency epinephrine. Those decisions should rest on better-validated markers (especially Ara h 2 IgE), clinical history, and your allergist's judgment.